CEP-751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity

International Journal of Cancer

Volumn 72, Issue 4, 1997, Pages 673-679

  Camoratto, Anna Marie ^a   Jani, Jitesh P ^a   Angeles, Thelma S ^a   Maroney, Anna C ^a   Sanders, Christa Y ^a   Murakata, Chikara ^b   Neff, Nicola T ^a   Vaught, Jeffry L ^a   Isaacs, John T ^c   Dionne, Craig A ^a  

^a CEPHALON INC   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 751; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CENTRAL NERVOUS SYSTEM TUMOR; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CARBAZOLES; ENZYME INHIBITORS; MICE; NERVE GROWTH FACTORS; PC12 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR; STIMULATION, CHEMICAL; TRANSFECTION; TYROSINE;

EID: 0030874174     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970807)72:4<673::AID-IJC20>3.0.CO;2-B     Document Type: Article

References (43)

1. AARONSON, S.A., Growth factors and cancer. Science, 254, 1146-1153 (1991).
2. AKINAGA, S., ASHIZAWA, T., GOMI, K., OHNO, H., MURIMOTO, M., MURAKATA, C. and OKABE, M., Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action. Cancer Chemother. Pharmacol., 2, 266-272 (1992).
3. AKINAGA, S., GOMI, K., MORIMOTO, M., TAMAOKI, T. and OKABE, M., Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 51, 4888-1892 (1991).
4. ANGELES, T.S., STEFFLER, C., BARTLETT, B.A., HUDKINS, R.L., STEPHENS, R.M., KAPLAN, D.R. and DIONNE, C.A., Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity. Anal. Biochem., 236, 49-55 (1996).
5. BERG, M.M., STERNBERG, D.W., PARADA, L.F. and CHAO, M.V., K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity. J. biol. Chem., 267, 13-16 (1992).
6. CORDON-CARDO, C., TAPLEY, P., JING, S., NANDURI, V., O'ROURKE, E., LAMBALLE, F., KOVARY, K., KLEIN, R., JONES, K.R., REICHARDT, L.F. and BARBACID, M., The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell, 66, 173-183 (1991).
7. DELVINCOURT, C., PATEY, M., FLAMENT, J.B., SUAREZ, H.G., LARBRE, H., JARDILLIER, J.C. and DELISLE, M.J., Ret and trk proto-oncogene activation in thyroid papillary carcinomas in French patients from the Champagne-Ardenne region. Clin. Biochem., 29, 267-271 (1996).
8. DIONNE, C.A., CRUMLEY, G., BELLOT, F., KAPLOW, J.M., SEARFOSS, G., RUTA, M., BURGESS, W.H., JAYE, M. and SCHLESSINGER, J., Cloning and expression of two distinct high affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J., 9, 2685-2692 (1990).
9. DONOVAN, M.J., HEMPSTEAD, B., HUBER, L.J., KAPLAN, D., TSOULFAS, P., CHAO, M., PARADA, L. and SCHOFIELD, D., Identification of the neurotrophin receptors p75 and trk in a series of Wilms' tumors. Amer. J. Pathol., 145, 792-801 (1994).
10. FRY, D.W., Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp. Opin. Invest. Drugs, 3, 577-595 (1994).
11. FUJITA-YAMAGUCHI, Y. and KATHURIA, S., Characterization of receptor tyrosine-specific protein kinases by the use of inhibitors. Staurosporine is a 100-times more potent inhibitor of insulin receptor than IGF-1 receptor. Biochem. biophys. Res. Comm., 157, 955-962 (1988).
12. GOTZ, R., KOSTER, R., WINKLER, C., RAULF, F., LOTTSPEICH, F., SCHARTL, M. and THOENEN, H., Neurotrophin-6 is a new member of the nerve growth factor family. Nature (Lond.), 372, 266-269 (1994).
13. HOEHNER, J.C., OLSEN, L., SANDSTEDT, B., KAPLAN, D.R. and PAHLMAN, S., Association of neurotrophin receptor expression and differentiation in human neuroblastoma. Amer. J. Pathol., 147, 102-113 (1995).
14. KAPLAN, D.R., MATSUMOTO, K., LUCARELLI, E. and THIELE, C.J., Induction of trkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Neuron, 11, 321-331 (1993).
15. KAPLAN, D.R. and STEPHENS, R.M., Neurotrophin signal transduction by the trk receptor. J. Neurobiol., 25, 1404-1417 (1994).
16. KASE, H., IWAHASHI, K. and MATSUDA, Y., K-252a, a potent inhibitor of protein kinase C from microbial origin. J. Antibiotics, 39, 1059-1065 (1986).
17. KOGNER, P., BARBANY, G., DOMINICI, C., CASTELLO, M.A., RASCHELLA, G. and PERSSON, H., Coexpression of messenger RNA for trk protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res., 53, 2044-2050 (1993).
18. MARONEY, A.C., LIPFERT, L., FORBES, M.E., GLICKSMAN, M.A., NEFF, N.T., SIMAN, R. and DIONNE, C.A., K-252a induces tyrosine phosphorylation of the focal adhesion kinase and neurite outgrowth in human neuroblastoma SH-SY5Y cells. J. Neurochem., 64, 540-549 (1995).
19. NTR. J. Neurochem., 68, 88-94 (1997).
20. MARTIN-ZANCA, D., HUGHES, S.H. and BARBACID, M., A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (Lond.), 319, 743-748 (1986).
21. MARTIN-ZANCA, D., OSKAM, R., MITRA, G., COPELAND, T. and BARBACID, M., Molecular and biochemical characterization of the human trk protooncogene. Mol. cell. Biol., 9, 24-33 (1989).
22. MEAKIN, S.O., SUTER, U., DRINKWATER, C.C., WELCHER, A.A. and SHOOTER, E.M., The rat trk proto-oncogene product exhibits properties characteristic of the slow nerve growth factor receptor. Proc. nat. Acad. Sci. (Wash.), 89, 2374-2378 (1992).
23. MEYER, S.L., LANG, D.M., FORBES, M.E., KNIGHT, E., JR., HIRSCH, J.D., TRUSKO, S.P. and SCOTT, R.W., Production and characterization of recombinant mouse brain-derived neurotrophic factor and rat neurotrophin-3 expressed in insect cells. J. Neurochem., 62, 825-833 (1994).
24. MISSALE, C., BORONI, F., LOSA, M., GIOVANELLI, M., ZANELLATO, A., DAL TOSO, R., BALSARI, A. and SPANO, P.-F., Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc. nat, Acad. Sci. (Wash.), 90, 7961-7965 (1993).
25. NAKAGAWARA, A., ARIMA, M., AZAR, C.G., SCAVARDA, N.J. and BRODEUR, G.M., Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res., 52, 1364-1368 (1992).
26. NAKAGAWARA, A., ARIMA-NAKAGAWARA, M., SCAVARDA, N.J., AZAR, C.G., CANTOR, A.B. and BRODEUR, G.M., Association between high levels of expression of the trk gene and favorable outcome in human neuroblastoma. N. Engl. J. Med., 328, 847-854 (1993).
27. NAKAGAWARA, A., AZAR, C.G., SCAVARDA, N.J. and BRODEUR, G.M., Expression and function of trkB and BDNF in human neuroblastomas. Mol. cell. Biol., 14, 759-767 (1994).
28. NAKANISHI, S., MATSUDA, Y, IWAHASHI, K. and KASE, H., K-252b, c and d, potent inhibitors of protein kinase C from microbial origin. J. Antibiotics, 39, 1066-1071 (1986).
29. NYE, S.H., SQUINTO, S.P., GLASS, D.J., STITT, T.N., HANTZOPOULOS, P., MACCHI, M.J., LINDSAY, N.S., IP, N.Y. and YANCOPOULOS, G., K-252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses. Mol. Biol. Cell, 3, 677-686 (1992).
30. OHMICHI, M., DECKER, S.J., PANG. L. and SALTIEL, A.R., Inhibition of the cellular actions of nerve growth factor by staurosporine and K252a results from the attenuation of the activity of the trk tyrosine kinase. Biochemistry, 31, 4034-4039 (1992).
31. OHMICHI, M., PANG, L., RIBON, V., GAZIT, A., LEVITZKI, A. and SALTIEL, A.R., The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. Biochemistry, 32, 4650-4658 ( 1993).
32. OMURA, S., SASAKI, Y., IWAI, Y. and TAKESHIMA, H., Staurosporine, a potentially important gift from a microorsanism. J. Antibiotics, 48, 535-548 (1995).
33. PAHLMAN, S. and HOEHNER, J.C., Neurotrophin receptors, tumor progression and tumor maturation. Mol. Med. Today, 2, 432-438 (1996).
34. PFLUG, B.R., DIONNE, C., KAPLAN, D.R., LYNCH, J. and DJAKIEW, D., Expression of a trk high affinity nerve growth factor receptor in the human prostate. Endocrinology, 136, 262-268 (1995).
35. PIEROTTI, M.A., BONGARZONE, I., BORRELLO, M.G., GRECO, A., PILOTTI, S. and SOZZI, G., Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer, 16, 1-14 (1996).
36. RAFFIONI, S. and BRADSHAW, R.A., The receptors for nerve growth factor and other neurotrophins. Ann. Rev. Biochem., 62, 823-850 (1993).
37. 2 domains of phospholipase C gamma. EMBO J., 11, 559-567 (1992).
38. SEGAL, R.A., GOUMNEROVA, L.C., KWON, Y.K., STILES, C.D. and POMEROY, S.L., Expression of the neurotrophin receptor trkC is linked to a favorable outcome in medulloblastoma. P roc. nat. Acad. Sci. (Wash.), 91, 12867-12871 (1994).
39. SUZUKI, T., BOGENMANN, E., SHIMADA, H., STRAM, D. and SEEGER, R.C., Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J. nat. Cancer Inst., 85, 377-384 (1993).
40. TAPLEY, P., LAMBALLE, F. and BARBACID, M., K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene, 7, 371-381 (1992).
41. TSOULFAS, P., SOPPET, D., ESCANDON, E., TESSAROLLO, L., MENDOZA-RAMIREZ, J.-L., ROSENTHAL, A., NIKOLICS, K. and PARADA, L.F., The rat trkC locus encodes multiple neurogenic receptors that exhibit differential response to neurotrophin-3 in PC-12 cells. Neuron, 10, 975-990 (1993).
42. WASHIYAMA, K., MURAGAKI, Y, RORKE, L.B., LEE, V.M.-Y., FEINSTEIN, S.C., RADEKE, M.J., BLUMBERG, D., KAPLAN, D.R. and TROJANOWSKI, J.Q., Neurotrophin and neurotrophin receptor proteins in medulloblastomas and other primitive neuroectodermal tumors of the pediatric central nervous system. Amer. J. Pathol., 148, 929-940 (1996).
43. WELS, W., HARWERTH, I.-M., MUELLER, M., GRONER, B. and HYNES, N.E., Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB2 receptor. Cancer Res., 52, 6310-6317 (1992).